Advertisement
Screener

Lyell Immunopharma, Inc. (LYEL) Operating Lease, Liability, Current

2.8 / 5 stars · 68/120 Roast Me

Lyell Immunopharma, Inc. Operating Lease, Liability, Current

Lyell Immunopharma, Inc. (LYEL) had Operating Lease, Liability, Current of $9.66 million as of 2026-06-30, per its 10-Q filed 2026-08-06.

Financial Statements › Notes › Leases

us-gaap:OperatingLeaseLiabilityCurrent · last filed 2026-08-06

  • 2026-06-30: Operating Lease, Liability, Current $9.66M.
  • 2026-03-31: Operating Lease, Liability, Current $9.36M.
  • 2025-12-31: Operating Lease, Liability, Current $9.07M.
  • 2025-09-30: Operating Lease, Liability, Current $8.79M.
Period endOperating Lease, Liability, Current
2026-06-30$9.66M
10-Q · filed 2026-08-06
2026-03-31$9.36M
10-Q · filed 2026-05-06
2025-12-31$9.07M
10-K · filed 2026-03-12
2025-09-30$8.79M
10-Q · filed 2025-11-12
2025-06-30$8.51M
10-Q · filed 2025-08-12
2025-03-31$8.24M
10-Q · filed 2025-05-13
2024-12-31$7.97M
10-K · filed 2026-03-12
2024-09-30$7.13M
10-Q · filed 2024-11-07
2024-06-30$6.90M
10-Q · filed 2024-08-07
2024-03-31$6.67M
10-Q · filed 2024-05-06
2023-12-31$6.27M
10-K · filed 2025-03-11
2023-09-30$6.06M
10-Q · filed 2023-11-07
2023-06-30$5.85M
10-Q · filed 2023-08-08
2023-03-31$4.81M
10-Q · filed 2023-05-04
2022-12-31$4.53M
10-K · filed 2024-02-28
2022-09-30$2.84M
10-Q · filed 2022-11-08
2022-06-30$1.48M
10-Q · filed 2022-08-04
2022-03-31$1.34M
10-Q · filed 2022-05-10
2021-12-31$1.17M
10-K · filed 2023-02-28
2020-12-31$3.62M
10-K · filed 2022-03-29

Similar stocks

Stock NameCountryMarket CapPE Ratio
Pyxis Oncology, Inc. (PYXS)United States$0.244B
Entrada Therapeutics, Inc. (TRDA)United States$0.243B-1.73
Cue Biopharma, Inc. (CUE)United States$0.243B-1.01
MACROGENICS INC (MGNX)United States$0.242B-20.11
Camp4 Therapeutics Corp (CAMP)United States$0.240B-2.12
Akebia Therapeutics, Inc. (AKBA)United States$0.255B-10.35
Sionna Therapeutics, Inc. (SION)United States$0.236B-20.37
SIGA TECHNOLOGIES INC (SIGA)United States$0.234B-93.33
Cartesian Therapeutics, Inc. (RNAC)United States$0.231B-2.04
Keros Therapeutics, Inc. (KROS)United States$0.229B-2.55